首页/数据集/Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children

Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children

NCATS Open Data2023-07-21 更新2026-08-08 收录

儿童新冠疫苗临床试验

Omicron变异株免疫原性

数据链接：

https://doi.org/10.1101/2023.06.23.23291767 数据链接链接失效反馈

官方服务：

资源简介：

Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in Children

应用场景：

创建时间：

2023-06-29

儿童新冠疫苗临床试验

疫苗安全性与免疫原性评估

Safe and effective vaccines against SARS-CoV-2 for children are urgently needed. Here we aimed to assess the safety and immunogenicity of an inactivated COVID-19 vaccine candidate, WIBP-CorV, in parti

NIAID Data Ecosystem20

Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children

儿童新冠疫苗临床试验

疫苗疗效预测

Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children

NCATS Open Data2022-03-11 更新10

Table_1_Immunogenicity, safety and consistency of seven lots of an inactivated COVID-19 vaccine in healthy children and adolescents: a randomized, double-blind, controlled, phase IV clinical trial.docx

儿童新冠疫苗临床试验

疫苗批次一致性评价

BackgroundCoronaVac has been authorized worldwide for preventing coronavirus disease 2019. Information on the safety, immunogenicity and consistency of different lots and workshops of CoronaVac is pre

NIAID Data Ecosystem00

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

儿童新冠疫苗临床试验

疫苗效力评估

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

NCATS Open Data2021-11-12 更新10

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

儿童新冠疫苗临床试验

儿科疫苗安全性与有效性

Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age

NCATS Open Data2022-05-27 更新10